Antibody–drug conjugate targeting TROP2; upon binding and internalization, releases a topoisomerase I inhibitor payload that induces DNA damage and tumor cell death, with potential bystander effect.
Humanized anti-TROP2 IgG1 ADC that binds TROP2 on tumor cells and is internalized; pH/enzymatic cleavage of the linker releases the topoisomerase I inhibitor tirumotecan, inhibiting Topo I, inducing DNA damage, replication arrest, and apoptosis, with a membrane-permeable payload enabling a bystander effect.
ADC binds TROP2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that induces DNA damage, replication arrest, and apoptosis; membrane-permeable payload can also cause a bystander effect.
IV chimeric anti-CD20 monoclonal antibody that depletes B cells via complement- and antibody-dependent cytotoxicity and apoptosis, reducing humoral immune activity and stabilizing podocyte injury.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby suppressing humoral immune activity and stabilizing podocyte injury.
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC, and can induce apoptosis, directly killing CD20+ cells.
Anti-CD20 monoclonal antibody that depletes B cells; used for EBV-PTLD prophylaxis and immune modulation.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and induces B‑cell depletion via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis; used to reduce B cells for EBV‑PTLD prophylaxis and immune modulation.
Anti-CD20 antibody binds CD20 on B cells and kills via Fc-mediated ADCC (NK cells/macrophages) and complement-dependent cytotoxicity; it can also induce apoptosis of CD20+ cells.
Rabbit polyclonal anti-T-cell globulin used for in vivo T-cell depletion and immunosuppression.
Rabbit polyclonal anti‑thymocyte globulin that binds multiple T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, adhesion/HLA molecules) and depletes T lymphocytes via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in potent in vivo T‑cell immunosuppression.
Rabbit polyclonal antibodies bind CD2 on T cells, triggering complement-dependent cytotoxicity and Fc-mediated ADCC, and can induce apoptosis, leading to direct depletion of CD2+ cells.